Innovative Pharmaceutical Biotech Limited (0399.HK) Comparison with companies in other sectors?

Innovative Pharmaceutical Biotech Limited has a share price of 1.99B. You can analyze Innovative Pharmaceutical Biotech Limited (0399.HK) competitors across different market sectors through stock heatmaps.

What are 0399.HK's NET and operating margins?

Innovative Pharmaceutical Biotech Limited (0399.HK) operating margin is around -3.22, and net profit margin is approximately 2.57 as of the latest reports.

In what way does 0399.HK's earnings per share (EPS) trend reflect its financial momentum?

Innovative Pharmaceutical Biotech Limited (0399.HK) EPS is -0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Innovative Pharmaceutical Biotech Limited is -53.00, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Innovative Pharmaceutical Biotech Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Innovative Pharmaceutical Biotech Limited like P/E which is 158.93, P/B which is -3.97, and PEG which is -0.85. Compare them with sector averages to evaluate if the stock is priced fairly.

Innovative Pharmaceutical Biotech Limited

0399.HK•HKSE

Consumer Defensive

Household & Personal Products

HK$0.53

HK$-0.10(-15.87%)

Innovative Pharmaceutical Biotech Limited (0399.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.01

P/E Ratio

-53.00

ROE

-0.02%

Net Margin

2.57%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.06B

Shares OutstandingTotal number of shares issued

$1.99B

Book Value/ShareNet worth per share

$0.14

Revenue/ShareAnnual revenue per share

$0.001

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.01

Net MarginNet income as percentage of revenue

256.75%

Operating MarginOperating income as percentage of revenue

-322.12%

ROEReturn on shareholders' equity

-2.14%

ROAReturn on total assets

0.83%

ROCEReturn on capital employed

-2.73%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.00

Cash/ShareCash and equivalents per share

$0.00

FCF YieldFree cash flow as percentage of market cap

-0.62%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 0399.HKFinancial Ratios Analysis details for 0399.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 0399.HKSector Benchmarking details for 0399.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Innovative Pharmaceutical Biotech Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Innovative Pharmaceutical Biotech Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Innovative Pharmaceutical Biotech Limited's unique business strengths and challenges.

Key Financial Metrics for Innovative Pharmaceutical Biotech Limited

For Innovative Pharmaceutical Biotech Limited, essential financial indicators include EPS -0.01, PE -53.00, and ROE -0.02. These key ratios reveal insights into Innovative Pharmaceutical Biotech Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare Innovative Pharmaceutical Biotech Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Innovative Pharmaceutical Biotech Limited

Metrics like Net Margin 256.75% and ROA 0.83% shed light on how well Innovative Pharmaceutical Biotech Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Innovative Pharmaceutical Biotech Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of Innovative Pharmaceutical Biotech Limited

Using ratios such as P/B Ratio -3.97 and PEG Ratio -0.85, investors can assess whether Innovative Pharmaceutical Biotech Limited is appropriately valued based on its financials and growth potential. These figures, combined with Innovative Pharmaceutical Biotech Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Innovative Pharmaceutical Biotech Limited

Financial health indicators, such as Debt/Equity Ratio -1.95 and Cash Flow $-0.00, provide a snapshot of Innovative Pharmaceutical Biotech Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Innovative Pharmaceutical Biotech Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Innovative Pharmaceutical Biotech Limited

Investing in Innovative Pharmaceutical Biotech Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Innovative Pharmaceutical Biotech Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;